| MeSH term | MeSH ID | Detail |
|---|---|---|
| Fibrosis | D005355 | 23 associated lipids |
| Fistula | D005402 | 8 associated lipids |
| Foot Diseases | D005534 | 4 associated lipids |
| Fractures, Open | D005597 | 3 associated lipids |
| Fusobacterium Infections | D005674 | 3 associated lipids |
| Gastritis | D005756 | 27 associated lipids |
| Gastritis, Atrophic | D005757 | 4 associated lipids |
| Gastritis, Hypertrophic | D005758 | 1 associated lipids |
| Gastroesophageal Reflux | D005764 | 10 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ramzy I et al. | GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. | 2016 | Rev. Inst. Med. Trop. Sao Paulo | pmid:27982354 |
| Gbinigie II and Lasserson D | Clarithromycin-induced akathisia: a class effect of macrolides? | 2016 | BMJ Case Rep | pmid:27927708 |
| Miftahussurur M et al. | Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. | 2016 | PLoS ONE | pmid:27906990 |
| Velu PP et al. | Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. | 2016 | Scott Med J | pmid:27872397 |
| Kasai C et al. | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. | 2016 | BMC Gastroenterol | pmid:27716077 |
| Noda H et al. | A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. | 2016 | J Gastrointestin Liver Dis | pmid:27689190 |
| Giorgio F et al. | Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. | 2016 | Scand. J. Gastroenterol. | pmid:27687850 |
| Donzelli A | Helicobacter pylori Eradication? | 2016 | Gastroenterology | pmid:27590693 |
| Sanches BS et al. | Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. | 2016 | World J. Gastroenterol. | pmid:27672279 |
| Patton PH et al. | Anti-tuberculous therapy for maintenance of remission in Crohn's disease. | 2016 | Cochrane Database Syst Rev | pmid:27444319 |
| Christl I et al. | Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. | 2016 | Environ. Sci. Technol. | pmid:27438991 |
| Luo XF et al. | Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. | 2016 | World J. Gastroenterol. | pmid:27433095 |
| Sakurai Y et al. | Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. | 2016 | Adv Ther | pmid:27432383 |
| Inagaki K et al. | Successful Treatment of Peritoneal Dialysis-related Peritonitis due to Mycobacterium iranicum. | 2016 | Intern. Med. | pmid:27432106 |
| Shiratori S et al. | Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection. | 2016 | Intern. Med. | pmid:27432094 |
| Furuta K et al. | 18 Cases of pulmonary Mycobacterium abscessus: Clinical difference depending on the presence or absence of Mycobacterium avium complex. | 2016 | J. Infect. Chemother. | pmid:27430867 |
| Zemali N et al. | Helicobacter pylori resistance to clarithromycin in Reunion Island. | 2016 | Med Mal Infect | pmid:27427280 |
| Hirasawa K et al. | Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. | 2016 | PLoS ONE | pmid:27977675 |
| Mougari F et al. | Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. | 2016 | Expert Rev Anti Infect Ther | pmid:27690688 |
| Laird-Fick HS et al. | Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. | 2016 | Postgrad Med J | pmid:27222587 |
| Phiphatpatthamaamphan K et al. | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. | 2016 | Asian Pac. J. Cancer Prev. | pmid:27221874 |
| Kim SY et al. | Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. | 2016 | BMC Infect. Dis. | pmid:27188784 |
| Suzuki S et al. | The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. | 2016 | Am. J. Gastroenterol. | pmid:27185079 |
| Garcia de Carvalho NF et al. | Resazurin Microtiter Assay for Clarithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group. | 2016 | J. Clin. Lab. Anal. | pmid:27169515 |
| Schuster S et al. | Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. | 2016 | Antimicrob. Agents Chemother. | pmid:27161641 |
| Li M et al. | Inducible Expression of both ermB and ermT Conferred High Macrolide Resistance in Streptococcus gallolyticus subsp. pasteurianus Isolates in China. | 2016 | Int J Mol Sci | pmid:27669217 |
| D'Erme AM et al. | Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. | 2016 | Int. J. Dermatol. | pmid:27028670 |
| Klesiewicz K et al. | Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. | 2016 | J. Antibiot. | pmid:27025351 |
| Kawashima K et al. | Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. | 2016 | Dig Liver Dis | pmid:27012448 |
| Ormeci A et al. | Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. | 2016 | Eur Rev Med Pharmacol Sci | pmid:27010145 |
| Dubini M et al. | Multiple drug allergy: A case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin. | 2016 | Ann. Allergy Asthma Immunol. | pmid:27009438 |
| Miyashita N et al. | Macrolide Therapy for Prevention of Exacerbation in Individuals with Diffuse Aspiration Bronchiolitis. | 2016 | J Am Geriatr Soc | pmid:27000351 |
| Shichijo S et al. | Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. | 2016 | Gastrointest. Endosc. | pmid:26995689 |
| Radzikowska E et al. | Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. | 2016 | Adv. Exp. Med. Biol. | pmid:26987326 |
| Wu DC et al. | A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. | 2016 | Medicine (Baltimore) | pmid:26986096 |
| Belz D et al. | Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. | 2016 | J Eur Acad Dermatol Venereol | pmid:25510444 |
| Vannarath S et al. | Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. | 2016 | Asian Pac. J. Cancer Prev. | pmid:26838225 |
| Miyamoto S et al. | Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. | 2016 | Tumour Biol. | pmid:26825980 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Kadota T et al. | Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. | 2016 | BMC Infect. Dis. | pmid:26818764 |
| Gaüzère BA and Malvy D | [Vingt-cinquième réunion du comité local de la Société de pathologie exotique, 24 novembre 2015]. | 2016 | Bull Soc Pathol Exot | pmid:26818816 |
| Tebruegge M et al. | Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis & Management at a Tertiary Center. | 2016 | PLoS ONE | pmid:26812154 |
| Fralick M et al. | Bleeding associated with coadministration of rivaroxaban and clarithromycin. | 2016 | CMAJ | pmid:26811362 |
| Berlin S et al. | Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. | 2016 | Mol. Pharm. | pmid:26808255 |
| Topp E et al. | Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. | 2016 | Sci. Total Environ. | pmid:27096634 |
| Li X et al. | Macrolides use and the risk of sudden cardiac death. | 2016 | Expert Rev Anti Infect Ther | pmid:27086751 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Boyanova L et al. | Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. | 2016 | Microb. Drug Resist. | pmid:26618567 |
| Villain J et al. | Acute toxicities of pharmaceuticals toward green algae. mode of action, biopharmaceutical drug disposition classification system and quantile regression models. | 2016 | Ecotoxicol. Environ. Saf. | pmid:26590695 |
| Geng S et al. | Clarithromycin ion pair in a liposomal membrane to improve its stability and reduce its irritation caused by intravenous administration. | 2016 | Expert Opin Drug Deliv | pmid:26588710 |
| Shin WG et al. | Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. | 2016 | Helicobacter | pmid:26470999 |
| Cerqueira RM et al. | How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? | 2016 | Obes Surg | pmid:26467690 |
| Boyanova L et al. | Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. | 2016 | Infect Dis (Lond) | pmid:26465202 |
| Lahmer T et al. | Pseudallescheria boydii with Aspergillus fumigatus and Aspergillus terreus in a Critically Ill Hematopoietic Stem Cell Recipient with ARDS. | 2016 | Mycopathologia | pmid:26455910 |
| Yoon H et al. | Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. | 2016 | Gut Liver | pmid:26347514 |
| Liou JM et al. | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. | 2016 | Gut | pmid:26338825 |
| Aguilera-Correa JJ et al. | Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. | 2017 | Diagn. Microbiol. Infect. Dis. | pmid:27863951 |
| Katayama Y et al. | Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. | 2017 | Life Sci. | pmid:27825902 |
| Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
| Moj D et al. | Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. | 2017 | AAPS J | pmid:27822600 |
| Angol DC et al. | from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. | 2017 | Biomed Res Int | pmid:28555193 |
| Akpinar Z et al. | Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. | 2017 | Arab J Gastroenterol | pmid:28532623 |
| Beckman E et al. | A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. | 2017 | J. Clin. Microbiol. | pmid:28515219 |
| Kajihara Y et al. | Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. | 2017 | Scand. J. Gastroenterol. | pmid:27806639 |
| Yan J et al. | Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital. | 2017 | Eur Arch Otorhinolaryngol | pmid:28508178 |
| Shaulov A et al. | Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. | 2017 | Am. J. Hematol. | pmid:27804150 |
| DaCosta A et al. | Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. | 2017 | J. Cyst. Fibros. | pmid:28495380 |
| Sharifi R et al. | Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. | 2017 | Lipids | pmid:28493185 |
| Reddy AB and Reddy ND | Development of Multiple-Unit Floating Drug Delivery System of Clarithromycin: Formulation, in vitro Dissolution by Modified Dissolution Apparatus, in vivo Radiographic Studies in Human Volunteers. | 2017 | Drug Res (Stuttg) | pmid:28449156 |
| Ivanová L et al. | Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. | 2017 | Environ. Res. | pmid:28183039 |
| Giguère S et al. | Antimicrobial Resistance in . | 2017 | Microbiol Spectr | pmid:29052538 |
| El Haj C et al. | The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? | 2017 | Med. Microbiol. Immunol. | pmid:27639707 |
| Seyama S et al. | Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). | 2017 | J. Antimicrob. Chemother. | pmid:27999037 |
| Giguère S | Treatment of Infections Caused by Rhodococcus equi. | 2017 | Vet. Clin. North Am. Equine Pract. | pmid:28161038 |
| Berni E et al. | Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. | 2017 | BMJ Open | pmid:28115334 |
| Serrano CA et al. | Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. | 2017 | J. Pediatr. Gastroenterol. Nutr. | pmid:27159208 |
| Yatera K et al. | The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. | 2017 | Respir Investig | pmid:29153420 |
| Lee MC et al. | Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. | 2017 | J. Antimicrob. Chemother. | pmid:29091186 |
| Takahashi C et al. | Morphological study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infection disease. | 2017 | Med Mol Morphol | pmid:27119723 |
| Laidler N | Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. | 2017 | BMJ Case Rep | pmid:29275384 |
| Lee JS et al. | Implication of species change of Nontuberculous Mycobacteria during or after treatment. | 2017 | BMC Pulm Med | pmid:29262802 |
| Ruiter R et al. | Helicobacter pylori resistance in the Netherlands: a growing problem? | 2017 | Neth J Med | pmid:29219812 |
| Kim SY et al. | Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. | 2017 | Helicobacter | pmid:28940815 |
| Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
| Tsay FW et al. | A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. | 2017 | Antimicrob. Agents Chemother. | pmid:28807915 |
| Oh ES et al. | Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. | 2017 | J Clin Pharm Ther | pmid:28806472 |
| Kuo YT et al. | Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. | 2017 | Lancet Gastroenterol Hepatol | pmid:28781119 |
| Ramas M et al. | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. | 2017 | Gastroenterol Hepatol | pmid:28780968 |
| Sue S et al. | The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. | 2017 | Intern. Med. | pmid:28566587 |
| Hu Y et al. | Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. | 2017 | Front Cell Infect Microbiol | pmid:28529929 |
| Jeong SH et al. | Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. | 2017 | Int. J. Infect. Dis. | pmid:28522316 |
| Kishida D et al. | Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus. | 2017 | Intern. Med. | pmid:28502947 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Sharman MJ et al. | Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. | 2017 | Vet. Immunol. Immunopathol. | pmid:28494926 |
| O'Brien CR et al. | Feline leprosy due to Candidatus 'Mycobacterium tarwinense':Further clinical and molecular characterisation of 15 previously reported cases and an additional 27 cases | 2017 | J. Feline Med. Surg. | pmid:28438086 |
| Zhang Z et al. | In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Int. J. Antimicrob. Agents | pmid:28188830 |
| Kristin F et al. | Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. | 2017 | Eur J Pharm Sci | pmid:28179133 |
| Chen D et al. | Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. | 2017 | Antimicrob. Agents Chemother. | pmid:28167563 |
| Olesen JS et al. | Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. | 2017 | BMJ Case Rep | pmid:28137898 |
| Chang JY et al. | Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. | 2017 | BMC Gastroenterol | pmid:28109257 |